Company Longboard Pharmaceuticals, Inc.

Equities

LBPH

US54300N1037

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:01 2024-05-16 pm EDT			5-day change	1st Jan Change
20.53 ^USD	-2.89%		-5.39%	+240.46%

May. 03	Wedbush Adjusts Longboard Pharmaceuticals' PT to $34 From $32, Keeps Outperform Rating	MT
May. 02	Longboard Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for neurological diseases. The Company is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). It is focused on developing various product candidates in its pipeline, which includes bexicaserin (LP352) and LP659. The Company plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. It is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. The Company is conducting a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.

Number of employees: 50

Managers	Title	Age	Since
Kevin Lind CEO	Chief Executive Officer	47	20-01-02
Brandi Roberts DFI	Director of Finance/CFO	50	20-12-31
Nuggehally Srinivas CTO	Chief Tech/Sci/R&D Officer	-	-
Dewey McLin CTO	Chief Tech/Sci/R&D Officer	-	-
Chadwick J. Orevillo COO	Chief Operating Officer	-	-
Randall Kaye CTO	Chief Tech/Sci/R&D Officer	61	22-03-20
Julie Baker PRN	Corporate Officer/Principal	-	22-12-31
Gus Cardenas PRN	Corporate Officer/Principal	-	-
Anne Danks PRN	Corporate Officer/Principal	-	-
Marco Peters PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Paul Sekhri CHM	Chairman	65	20-11-30
Phillip Schneider BRD	Director/Board Member	67	20-11-30
Vincent Aurentz BRD	Director/Board Member	56	20-01-31
Casey Lynch BRD	Director/Board Member	50	21-01-31
Kevin Lind CEO	Chief Executive Officer	47	20-01-02
Corinne Le Goff BRD	Director/Board Member	58	21-02-28
Jane Tiller BRD	Director/Board Member	64	21-11-14

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	5,270,755	0	0	85.50 %
Stock B	1	33,609,299	33,242,929 ( 98.91 %)	0

Name	Equities	%	Valuation
Farallon Capital Management LLC 17.24 %	5,790,500	17.24 %	111 M $
Fidelity Management & Research Co. LLC 13.47 %	4,525,070	13.47 %	87 M $
Cormorant Asset Management LP 9.981 %	3,353,141	9.981 %	65 M $
RA Capital Management LP 9.790 %	3,289,119	9.790 %	63 M $
RA Capital Management LP 9.147 %	3,073,119	9.147 %	59 M $
T. Rowe Price International Ltd. 6.602 %	2,217,995	6.602 %	43 M $
Wellington Management Co. LLP 6.359 %	2,136,363	6.359 %	41 M $
BlackRock Advisors LLC 5.328 %	1,790,175	5.328 %	34 M $
Vanguard Fiduciary Trust Co. 5.133 %	1,724,431	5.133 %	33 M $
Point72 Asset Management LP 4.093 %	1,375,000	4.093 %	26 M $

Name	Equities	%	Valuation
Cormorant Asset Management LP 18.22 %	661,255	18.22 %	13 M $
Farallon Capital Management LLC 17.79 %	645,490	17.79 %	12 M $

Longboard Pharmaceuticals, Inc.

4275 Executive Square Suite 950

92037, La Jolla

http://www.longboardpharma.com

address Longboard Pharmaceuticals, Inc.(LBPH)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

20.53 USD

Average target price

42 USD

Spread / Average Target

+104.58%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
LONGBOARD PHARMACEUTICALS, INC.	+240.46%	822M
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	113B
REGENERON PHARMACEUTICALS, INC.	+10.21%	106B
ARGENX SE	+0.41%	22.27B
BIONTECH SE	-11.90%	22.22B
GENMAB A/S	-5.99%	19.43B
WUXI APPTEC CO., LTD.	-37.36%	17.87B
BEIGENE, LTD.	-5.17%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	14.29B
SAREPTA THERAPEUTICS, INC.	+37.65%	12.52B

Bio Therapeutic Drugs